GEN Exclusives

More »

GEN News Highlights

More »
May 9, 2007

NovaThera and Gamida Cell Join Forces to Develop Cell Therapeutics for Lung Disease

  • NovaThera and Gamida Cell are partnering to develop cell therapeutic treatments for lung repair and regeneration. The companies will pool technology and expertise and work together with the clinical team at Papworth Hospital in the U.K. toward advancing cell therapy approaches for treating lung disease.

    NovaThera specializes in applications of biomaterials and stem cell biology for regenerative medicine and tissue engineering. Gamida Cell develops therapeutics using technologies that expand populations of hematopoietic stem/progenitor cells such as those derived from cord blood for the treatment of hematological diseases as well as for tissue regeneration applications.

    The companies believe that considerable advances in treating lung disease could come from using stem cells to repair and regenerate damaged tissues. Toward this goal, the scientists at Papworth will clinically test populations of cord blood-derived stem cells, expanded by Gamida Cell's stem/progenitor cell expansion technologies.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?